Interleukins in Churg-Strauss syndrome.
Kurosawa
M
M
Department of Clinical and Laboratory Medicine, Akita University School of Medicine, Japan. motohiro@hos.akita-u.ac.jp
Nakagami
R
R
Morioka
J
J
Inamura
H
H
Mizushima
Y
Y
Sugawara
N
N
Yamashita
T
T
Yokoseki
T
T
Kitamura
S
S
Omura
Y
Y
Shibata
M
M
Chihara
J
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001798:Blood Proteins / Q000096:biosynthesis; D015267:Churg-Strauss Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism*; D047091:Eosinophil Granule Proteins; D047208:Eosinophil-Derived Neurotoxin; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D018793:Interleukin-13 / Q000096:biosynthesis*; D015847:Interleukin-4 / Q000096:biosynthesis*; D015848:Interleukin-5 / Q000096:biosynthesis*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D014176:Protein Biosynthesis; D012260:Ribonucleases
D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D005938:Glucocorticoids; D018793:Interleukin-13; D015848:Interleukin-5; D015847:Interleukin-4; D011239:Prednisolone; D047208:Eosinophil-Derived Neurotoxin; D012260:Ribonucleases